Global Computational Biology Market: Key Developments
On October 14, 2020, Summit Biolabs, a U.S.-based medical laboratory announced a broad strategic collaboration involving the research, development, and commercialization of saliva liquid-biopsy tests for early cancer detection and diagnosis of COVID-19 and other viral contagions with Colorado Center for Personalized Medicine, a U.S.-based biorepository. This collaboration broadened and strengthened Summit Biolabs’ ability to bring saliva liquid-biopsy tests to enable better treatment and improved outcomes for patients.
On June 24, 2020, AsclepiX Therapeutics, Inc., a U.S.-based biotechnology company, announced that it has closed a US$ 35 million Series A financing led by Perceptive Xontogeny Venture Fund. The proceeds from financing will fund Phase 1/2a clinical trials of AXT107, the company’s investigational drug.
On January 20, 2022, Researchers from the University of Illinois at Urbana-Champaign, a U.S.-based research university, developed Graphics Processing Unit (GPU)-accelerated software to simulate a 2-billion-atom cell that metabolizes and shows growth similar that of a living cell in the body. The model uses NVIDIA, a U.S.-based technology company’s product, GPUs to simulate 7,000 genetic information processes over a 20-minute span of the cell cycle.
On November 10, 2020, PerkinElmer Inc., a U.S.-based pharmaceutical products company, announced the release of ChemDraw and ChemOffice+ Cloud version 20.0, a Research Suite designed to help researchers bring their chemistry to life and quickly turn it into actionable chemical knowledge.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients